Lilly(US:LLY) GLP1减重宝典·2025-11-25 12:01Core Insights - The article discusses the recent developments regarding Eli Lilly's GLP-1 receptor agonist, orforglipron, particularly its Phase 3 ATTAIN-Outcomes trial aimed at assessing cardiovascular outcomes in patients with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD) [2][3][4] - The ATTAIN-2 trial results for orforglipron in overweight or obese adults with type 2 diabetes showed significant weight loss and improvements in metabolic parameters, which have positively influenced market confidence [5][8][9] Group 1: Clinical Trials - Eli Lilly registered the Phase 3 ATTAIN-Outcomes trial on November 21, 2025, with an estimated enrollment of 7,140 participants and a follow-up period of five years, expected to complete by August 2031 [2][3][4] - The ATTAIN-2 trial involved a 72-week study where participants taking the highest dose of 36 mg lost an average of 10.5% of their body weight, equating to approximately 22.9 pounds [5][7] - All dosage groups in the ATTAIN-2 trial achieved weight loss, with the 12 mg group averaging a 7.8% reduction and the 6 mg group a 5.5% reduction, compared to a 2.2% reduction in the placebo group [7] Group 2: Market Impact and Future Prospects - The positive results from the ATTAIN-2 trial have restored market confidence regarding orforglipron's potential market share, especially in the diabetes treatment sector, which affects about 15% of U.S. adults [9] - Eli Lilly plans to present complete data at future medical conferences and is preparing for global regulatory submissions, indicating a strong commitment to advancing orforglipron's market presence [8][9] - The results from ATTAIN-2 contrast with the earlier ATTAIN-1 trial, which showed a 12.4% weight loss in a non-diabetic obese population but faced cautious market reactions due to competitive data [8]